Pharmaceutical Restructuring Valuation 
Musings on Markets
FEBRUARY 18, 2025
Carrying this through to the real world, you should not be surprised to see technology and pharmaceutical companies, the two biggest spenders on R&D, report much higher accounting returns than they are actually earning on their investments.
CFO News Room
JANUARY 18, 2023
Even though we live in an age where user platforms and hyper revenue growth can drive company valuations, that adage remains true. To the extent that accountants mis-categorize expenses like leases and R&D, returns can be skewed, as can restructuring and one-time charges.
Musings on Markets
FEBRUARY 27, 2022
Even though we live in an age where user platforms and hyper revenue growth can drive company valuations, that adage remains true. To the extent that accountants mis-categorize expenses like leases and R&D, returns can be skewed, as can restructuring and one-time charges.
Expert insights. Personalized for you.
Let's personalize your content